– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 trial –...
Clinical trial application for pivotal JTA-004 Phase III study submitted Start patient enrollment anticipated early 2020 with topline results expected in Q2 2021 BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the...
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass., Dec. 18,...
– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 trial –...
First-in-human safety and tolerability Phase 2 clinical trial ‘Danube’ in 36 patients met primary objective of selecting the dose of NCX 4251 for further development NCX 4251 0.1% once daily (QD) treatment was selected to advance into larger Phase 2b clinical trial,...
Email
Text